[1]
|
Guy, G.P., Machlin, S.R., Ekwueme, D.U. and Yabroff, K.R. (2015) Prevalence and Costs of Skin Cancer Treatment in the U.S., 2002-2006 and 2007-2011. American Journal of Preventive Medicine, 48, 183-187. https://doi.org/10.1016/j.amepre.2014.08.036
|
[2]
|
刘杰, 朱丽萍, 杨旭丽, 等. 2014年中国皮肤黑色素瘤发病与死亡分析[J]. 中国肿瘤. 2018, 27(4): 241-245. https://doi.org/10.11735/j.issn.1004-0242.2018.04.A001
|
[3]
|
Craig, S., Earnshaw, C.H. and Virós, A. (2018) Ultraviolet Light and Melanoma. The Journal of Pathology, 244, 578-585. https://doi.org/10.1002/path.5039
|
[4]
|
王一芩, 周佳磊, 白凯文, 等. 黑色素瘤的发病机制和治疗方法研究进展[J] . 药物生物技术, 2019, 26(4): 357-361. https://doi.org/10.19526/j.cnki.1005-8915.20190417
|
[5]
|
Sample, A. and He, Y. (2017) Mechanisms and Prevention of UV-Induced Melanoma. Photodermatology, Photoimmunology & Photomedicine, 34, 13-24. https://doi.org/10.1111/phpp.12329
|
[6]
|
Shah, P. and He, Y. (2015) Molecular Regulation of UV‐Induced DNA Repair. Photochemistry and Photobiology, 91, 254-264. https://doi.org/10.1111/php.12406
|
[7]
|
Burns, D., George, J., Aucoin, D., Bower, J., Burrell, S., Gilbert, R., et al. (2019) The Pathogenesis and Clinical Management of Cutaneous Melanoma: An Evidence-Based Review. Journal of Medical Imaging and Radiation Sciences, 50, 460-469.E1. https://doi.org/10.1016/j.jmir.2019.05.001
|
[8]
|
Pampena, R., Kyrgidis, A., Lallas, A., Moscarella, E., Argenziano, G. and Longo, C. (2017) A Meta-Analysis of Nevus-Associated Melanoma: Prevalence and Practical Implications. Journal of the American Academy of Dermatology, 77, 938-945.E4. https://doi.org/10.1016/j.jaad.2017.06.149
|
[9]
|
郭婷婷, 图荪阿依∙吾麦尔, 胡佳捷, 等. 皮肤黑色素瘤患者的预后及影响因素分析[J]. 癌症进展, 2024, 22(2): 141-145.
|
[10]
|
Cust, A.Ε., Mishra, K. and Berwick, M. (2018) Melanoma–role of the Environment and Genetics. Photochemical & Photobiological Sciences, 17, 1853-1860. https://doi.org/10.1039/c7pp00411g
|
[11]
|
Li, W., Han, J., Widlund, H.R., Correll, M., Wang, Y.E., Quackenbush, J., et al. (2013) CXCR4 Pathway Associated with Family History of Melanoma. Cancer Causes & Control, 25, 125-132. https://doi.org/10.1007/s10552-013-0315-9
|
[12]
|
Brandt, A., Sundquist, J. and Hemminki, K. (2011) Risk of Incident and Fatal Melanoma in Individuals with a Family History of Incident or Fatal Melanoma or Any Cancer. British Journal of Dermatology, 165, 342-348. https://doi.org/10.1111/j.1365-2133.2011.10350.x
|
[13]
|
Jones, M.S., Jones, P.C., Stern, S.L., Elashoff, D., Hoon, D.S.B., Thompson, J., et al. (2017) The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma. Annals of Surgical Oncology, 24, 2089-2094. https://doi.org/10.1245/s10434-017-5775-9
|
[14]
|
Utjés, D., Malmstedt, J., Teras, J., Drzewiecki, K., Gullestad, H.P., Ingvar, C., et al. (2019) 2-cm versus 4-cm Surgical Excision Margins for Primary Cutaneous Melanoma Thicker than 2 Mm: Long-Term Follow-Up of a Multicentre, Randomised Trial. The Lancet, 394, 471-477. https://doi.org/10.1016/s0140-6736(19)31132-8
|
[15]
|
张鹏晓, 胡念. 黑色素瘤免疫治疗作用机制研究进展[J]. 生物技术进展, 2023, 13(6): 900-906. https://doi.org/10.19586/j.2095-2341.2023.0094
|
[16]
|
Wohlmuth, C. and Wohlmuth-Wieser, I. (2021) Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment. American Journal of Clinical Dermatology, 22, 639-651. https://doi.org/10.1007/s40257-021-00614-7
|
[17]
|
Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., et al. (2017) Dabrafenib Plus Trametinib versus Dabrafenib Monotherapy in Patients with Metastatic BRAF V600e/k-Mutant Melanoma: Long-Term Survival and Safety Analysis of a Phase 3 Study. Annals of Oncology, 28, 1631-1639. https://doi.org/10.1093/annonc/mdx176
|
[18]
|
Dummer, R., Ascierto, P.A., Gogas, H.J., Arance, A., Mandala, M., Liszkay, G., et al. (2018) Encorafenib Plus Binimetinib versus Vemurafenib or Encorafenib in Patients with BRAF-Mutant Melanoma (COLUMBUS): A Multicentre, Open-Label, Randomised Phase 3 Trial. The Lancet Oncology, 19, 603-615. https://doi.org/10.1016/s1470-2045(18)30142-6
|
[19]
|
孟燕, 蒋明东, 张献全. 黑色素瘤免疫治疗研究进展[J]. 现代医药卫生, 2020, 36(11): 1677-1680. https://doi.org/10.3969/j.issn.1009-5519.2020.11.022
|
[20]
|
Eggermont, A.M.M., Crittenden, M. and Wargo, J. (2018) Combination Immunotherapy Development in Melanoma. American Society of Clinical Oncology Educational Book, 38, 197-207. https://doi.org/10.1200/edbk_201131
|
[21]
|
Carr, S., Smith, C. and Wernberg, J. (2020) Epidemiology and Risk Factors of Melanoma. Surgical Clinics of North America, 100, 1-12. https://doi.org/10.1016/j.suc.2019.09.005
|